Swiss National Bank boosted its holdings in Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) by 14.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 101,100 shares of the biopharmaceutical company’s stock after purchasing an additional 13,100 shares during the period. Swiss National Bank’s holdings in Cara Therapeutics were worth $1,228,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Rafferty Asset Management LLC purchased a new position in shares of Cara Therapeutics in the 4th quarter worth about $173,000. Qube Research & Technologies Ltd bought a new stake in Cara Therapeutics in the first quarter worth about $207,000. Baldwin Brothers LLC MA boosted its stake in Cara Therapeutics by 41.0% in the first quarter. Baldwin Brothers LLC MA now owns 18,327 shares of the biopharmaceutical company’s stock valued at $223,000 after acquiring an additional 5,327 shares during the last quarter. ProShare Advisors LLC grew its position in shares of Cara Therapeutics by 6.1% during the 4th quarter. ProShare Advisors LLC now owns 18,555 shares of the biopharmaceutical company’s stock valued at $226,000 after acquiring an additional 1,075 shares during the period. Finally, First Citizens Bank & Trust Co. purchased a new stake in shares of Cara Therapeutics during the 1st quarter worth approximately $246,000. Institutional investors own 65.00% of the company’s stock.
Wall Street Analysts Forecast Growth
Separately, StockNews.com upgraded Cara Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, May 13th. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $27.00.
Insider Transactions at Cara Therapeutics
Cara Therapeutics Stock Down 2.1 %
NASDAQ CARA opened at $10.64 on Monday. The company has a market cap of $571.64 million, a PE ratio of -8.51 and a beta of 1.02. Cara Therapeutics, Inc. has a 52 week low of $7.40 and a 52 week high of $18.93. The firm’s 50-day simple moving average is $10.03 and its two-hundred day simple moving average is $10.25.
Cara Therapeutics (NASDAQ:CARA – Get Rating) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.20. Cara Therapeutics had a negative net margin of 135.72% and a negative return on equity of 31.47%. The company had revenue of $23.00 million for the quarter, compared to analysts’ expectations of $21.28 million. As a group, equities research analysts anticipate that Cara Therapeutics, Inc. will post -1.34 EPS for the current year.
Cara Therapeutics Profile
Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
- Get a free copy of the StockNews.com research report on Cara Therapeutics (CARA)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.